🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06278675
Starting soon Not applicable

Multiple Study of Electroaccpuncture in ARDS

NCT06278675 · tracked via the Priya Life Science China tracker
Sponsor
Nanjing University of Traditional Chinese Medicine
Phase
Not applicable
Started
2024-05-10
Last updated
2024-04-23

Condition(s) studied

Acute Respiratory Distress SyndromeSepsis

Investigational drug(s) / intervention(s)

Acupuncture needles

Acupuncture needles: 1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days. 2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.

Study summary

In order to clarify the clinical efficacy of electroacupuncture on inhibiting systemic inflammatory response, improving respiratory mechanics parameters and prognosis in patients with sepsis-related ARDS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Meet the diagnostic criteria of the Surviving Sepsis Campaign: Updated International Guidelines for the Treatment of Sepsis and Septic Shock 2021 * Meet the diagnostic criteria of the European Society of Critical Care Medicine (ESICM) Guidelines for Acute Respiratory Distress Syndrome: Definition, Phenotype and Respiratory Support Strategies * Age \>18 years * Expected duration of mechanical ventilation\>48 hours * Expected ICU stay of more than 7 days * Signed informed consent. Exclusion Criteria: * Participated in other clinical trials * Pregnant, lactating or miscarriage * Patients with disseminated tumors or tumors receiving chemotherapy and other special treatments * Alcohol abuse * Severe cardiovascular, brain, liver, kidney, psychiatric diseases, diabetes, multiple system atrophy, cauda equina injury or myelopathy * Systolic blood pressure \< 90mmHg within 2 hours before the start of the study * Severe burns or severe skin diseases * Pacemaker placement, metal allergy or severe needle sickness * Abnormal coagulation function

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine Nanjing Jiangsu

More Nanjing University of Traditional Chinese Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06278675 on ClinicalTrials.gov ↗ ← All trials in China